Neutral
Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M
Pliant Therapeutics (NASDAQ: PLRX) significantly reduced its net loss to $20.0 million in Q1 2026 from $56.2 million in Q1 2025, primarily due to rest...